PortfoliosLab logoPortfoliosLab logo
SPRY vs. EWTX
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Performance

SPRY vs. EWTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Silverback Therapeutics Inc (SPRY) and Edgewise Therapeutics Inc (EWTX). The values are adjusted to include any dividend payments, if applicable.

Loading graphics...

SPRY vs. EWTX - Yearly Performance Comparison


2026 (YTD)20252024202320222021
SPRY
Silverback Therapeutics Inc
-31.07%10.43%92.52%-35.76%28.08%-85.92%
EWTX
Edgewise Therapeutics Inc
26.94%-7.06%144.06%22.37%-41.49%-49.07%

Fundamentals

Market Cap

SPRY:

$791.49M

EWTX:

$3.24B

EPS

SPRY:

-$1.74

EWTX:

-$1.61

PB Ratio

SPRY:

6.93

EWTX:

6.21

Total Revenue (TTM)

SPRY:

$84.28M

EWTX:

$0.00

Gross Profit (TTM)

SPRY:

$45.85M

EWTX:

$0.00

EBITDA (TTM)

SPRY:

-$175.98M

EWTX:

-$191.41M

Returns By Period

In the year-to-date period, SPRY achieves a -31.07% return, which is significantly lower than EWTX's 26.94% return.


SPRY

1D
2.75%
1M
-13.47%
YTD
-31.07%
6M
-20.10%
1Y
-36.17%
3Y*
7.25%
5Y*
-28.93%
10Y*

EWTX

1D
4.03%
1M
3.48%
YTD
26.94%
6M
94.20%
1Y
43.18%
3Y*
67.78%
5Y*
0.97%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Silverback Therapeutics Inc

Edgewise Therapeutics Inc

Return for Risk

SPRY vs. EWTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SPRY
SPRY Risk / Return Rank: 2121
Overall Rank
SPRY Sharpe Ratio Rank: 1717
Sharpe Ratio Rank
SPRY Sortino Ratio Rank: 1919
Sortino Ratio Rank
SPRY Omega Ratio Rank: 2020
Omega Ratio Rank
SPRY Calmar Ratio Rank: 2323
Calmar Ratio Rank
SPRY Martin Ratio Rank: 2424
Martin Ratio Rank

EWTX
EWTX Risk / Return Rank: 6060
Overall Rank
EWTX Sharpe Ratio Rank: 6161
Sharpe Ratio Rank
EWTX Sortino Ratio Rank: 6363
Sortino Ratio Rank
EWTX Omega Ratio Rank: 6363
Omega Ratio Rank
EWTX Calmar Ratio Rank: 5858
Calmar Ratio Rank
EWTX Martin Ratio Rank: 5555
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

SPRY vs. EWTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Silverback Therapeutics Inc (SPRY) and Edgewise Therapeutics Inc (EWTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


SPRYEWTXDifference

Sharpe ratio

Return per unit of total volatility

-0.54

0.55

-1.09

Sortino ratio

Return per unit of downside risk

-0.50

1.30

-1.80

Omega ratio

Gain probability vs. loss probability

0.94

1.18

-0.23

Calmar ratio

Return relative to maximum drawdown

-0.56

0.74

-1.30

Martin ratio

Return relative to average drawdown

-0.97

1.31

-2.28

SPRY vs. EWTX - Sharpe Ratio Comparison

The current SPRY Sharpe Ratio is -0.54, which is lower than the EWTX Sharpe Ratio of 0.55. The chart below compares the historical Sharpe Ratios of SPRY and EWTX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Loading graphics...

Sharpe Ratios by Period


SPRYEWTXDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-0.54

0.55

-1.09

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.36

0.01

-0.37

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.24

0.01

-0.25

Correlation

The correlation between SPRY and EWTX is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


Dividends

SPRY vs. EWTX - Dividend Comparison

Neither SPRY nor EWTX has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SPRY vs. EWTX - Drawdown Comparison

The maximum SPRY drawdown since its inception was -95.20%, which is greater than EWTX's maximum drawdown of -84.69%. Use the drawdown chart below to compare losses from any high point for SPRY and EWTX.


Loading graphics...

Drawdown Indicators


SPRYEWTXDifference

Max Drawdown

Largest peak-to-trough decline

-95.20%

-84.69%

-10.51%

Max Drawdown (1Y)

Largest decline over 1 year

-63.32%

-43.27%

-20.05%

Max Drawdown (5Y)

Largest decline over 5 years

-93.45%

-81.79%

-11.66%

Current Drawdown

Current decline from peak

-86.71%

-13.98%

-72.73%

Average Drawdown

Average peak-to-trough decline

-77.98%

-55.23%

-22.75%

Ulcer Index

Depth and duration of drawdowns from previous peaks

36.73%

27.07%

+9.66%

Volatility

SPRY vs. EWTX - Volatility Comparison

Silverback Therapeutics Inc (SPRY) has a higher volatility of 17.65% compared to Edgewise Therapeutics Inc (EWTX) at 12.84%. This indicates that SPRY's price experiences larger fluctuations and is considered to be riskier than EWTX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading graphics...

Volatility by Period


SPRYEWTXDifference

Volatility (1M)

Calculated over the trailing 1-month period

17.65%

12.84%

+4.81%

Volatility (6M)

Calculated over the trailing 6-month period

51.95%

55.95%

-4.00%

Volatility (1Y)

Calculated over the trailing 1-year period

67.04%

78.84%

-11.80%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

80.53%

80.73%

-0.20%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

81.43%

81.37%

+0.06%

Financials

SPRY vs. EWTX - Financials Comparison

This section allows you to compare key financial metrics between Silverback Therapeutics Inc and Edgewise Therapeutics Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00MAprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober
28.09M
0
(SPRY) Total Revenue
(EWTX) Total Revenue
Values in USD except per share items